<DOC>
	<DOCNO>NCT00495144</DOCNO>
	<brief_summary>This phase I , multi-center , open-label , dose-escalation study TH-302 patient advance solid tumor . TH-302 hypoxia activate product design exploit hypoxic nature tumor . The study design establish safety include maximum tolerated dose , pharmacokinetics , anti-tumor activity TH-302 .</brief_summary>
	<brief_title>A Phase I Study Safety , Pharmacokinetics , Anti-Tumor Activity TH-302 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Anoxia</mesh_term>
	<criteria>At least 18 year age Ability understand purpose risk study sign write informed consent form approve investigator 's IRB/Ethics Committee Histologically cytologically confirm advanced metastatic solid malignancy Advanced metastatic solid malignancy previously treat one regimens chemotherapy effective therapy available Recovered toxicity prior therapy Measurable disease RECIST criterion ( least one target lesion ) ECOG performance status 0 1 Life expectancy least 3 month Acceptable liver function : Bilirubin ≤ 1.5 time upper limit normal AST ( SGOT ) ALT ( SGPT ) ≤ 2.5 time upper limit normal ( ULN ) ; liver metastases present , ≤ 5 x ULN allow Acceptable renal function : Serum creatinine ≤ ULN Acceptable hematologic status ( without hematologic support ) : ANC ≥ 1500 cells/μL Platelet count ≥ 100,000/μL Hemoglobin ≥ 9.0 g/dL Urinalysis : No clinically significant abnormality Acceptable coagulation status : PT ≤ 1.3 x ULN PTT ≤ 1.3 x ULN All woman childbearing potential must negative serum pregnancy test woman men subject must agree use effective mean contraception ( surgical sterilization use barrier contraception either condom diaphragm conjunction spermicidal gel IUD ) partner entry study 6 month last dose Prior treatment high dose chemotherapy Prior radiotherapy 25 % bone marrow New York Heart Association ( NYHA ) Class III IV , cardiac disease , myocardial infarction within 6 month prior Day 1 , unstable arrhythmia Seizure disorder require anticonvulsant therapy Symptomatic brain metastasis ( unless previously treat well controlled period ≥ 3 month ) Severe chronic obstructive pulmonary disease hypoxemia opinion investigator physiological state lead hypoxemia Major surgery , diagnostic surgery , within 4 week prior Day 1 , without complete recovery Active , uncontrolled bacterial , viral , fungal infection , require systemic therapy Treatment radiation therapy , surgery , chemotherapy , target therapy ( erlotinib , lapatinib , etc . ) hormone within 4 week prior study entry ( 6 week nitrosoureas Mitomycin C ) Patients participate investigational drug device study within 28 day prior study entry Known infection HIV , hepatitis B , hepatitis C Patients exhibit allergic reaction similar structural compound , biological agent , formulation ( contain solutol and/or propylene glycol ) Females pregnant breastfeeding Concomitant disease condition could interfere conduct study , would , opinion investigator , pose unacceptable risk subject study Unwillingness inability comply study protocol reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Advanced Solid Tumors</keyword>
	<keyword>Hypoxia</keyword>
	<keyword>Prodrug</keyword>
	<keyword>Multi-Center</keyword>
	<keyword>Open-Label</keyword>
	<keyword>Dose-Escalation</keyword>
</DOC>